$Viking Therapeutics (VKTX.US)$ Results from the 28-day MAD ...
$Viking Therapeutics(VKTX.US$
Results from the 28-day MAD study highlighted positive signs of clinical activity after oral VK2735 treatment. The group receiving VK2735 showed a decrease in average body weight compared to baseline, by as much as 5.3%. Compared to placebo, the average body weight of the group receiving VK2735 also decreased by as much as 3.3%. For doses greater than or equal to 10 mg, the average weight loss after placebo was maintained or improved on day 34, six days after the last dose of VK2735, as much as 3.6% compared to placebo. An exploratory evaluation of the proportion of subjects who lost at least 5% of their weight after 28 days showed that as many as 57% of those treated with VK2735 lost more than 5% of their weight, compared to 0% with placebo. Based on an initial assessment of the weight loss trajectory, the company believes that treatment over 28 days can lead to further weight loss.
“These first phase results highlight the promising early weight loss and tolerability of VK2735 in oral tablet doses,” said Dr. Brian Lien, CEO of Viking. “We think these data suggest that, at possibly higher doses, it may result in longer treatment times
Results from the 28-day MAD study highlighted positive signs of clinical activity after oral VK2735 treatment. The group receiving VK2735 showed a decrease in average body weight compared to baseline, by as much as 5.3%. Compared to placebo, the average body weight of the group receiving VK2735 also decreased by as much as 3.3%. For doses greater than or equal to 10 mg, the average weight loss after placebo was maintained or improved on day 34, six days after the last dose of VK2735, as much as 3.6% compared to placebo. An exploratory evaluation of the proportion of subjects who lost at least 5% of their weight after 28 days showed that as many as 57% of those treated with VK2735 lost more than 5% of their weight, compared to 0% with placebo. Based on an initial assessment of the weight loss trajectory, the company believes that treatment over 28 days can lead to further weight loss.
“These first phase results highlight the promising early weight loss and tolerability of VK2735 in oral tablet doses,” said Dr. Brian Lien, CEO of Viking. “We think these data suggest that, at possibly higher doses, it may result in longer treatment times
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
